Oxytrol OTC Success Depends On Driving Behavioral Changes

01 Nov 2013

• By Malorye Allison

Merck’s Oxytrol for Women could set the stage for other OTC switches indicated for chronic conditions, but the lifestyle changes recommended with the drug could be a hurdle. Oxytrol faces similar challenges to alli, another first-in-class switch with behavioral changes recommended.

Success for the Oxytrol for Women patch for overactive bladder will depend partly on Merck & Co. Inc. overcoming some of the target population’s likely hesitancy to make behavioral changes linked to its efficacy.

If Merck’s marketing succeeds, the first-in-class OTC switch Oxytrol for Women (transdermal 3.9 mg oxybutynin) could become a blueprint for...